Roubaix Capital’s Health Catalyst HCAT Stock Holding History

Roubaix Capital’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-31,889	Closed	-$1.17M	–	57
2020 Q3	$1.17M	Buy	+31,889	New	+$1.08M	1.38%	37
2020 Q2	–	Sell	-39,722	Closed	-$1.04M	–	59
2020 Q1	$1.04M	Buy	+39,722	New	+$1.21M	1.58%	31

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Roubaix Capital's HCAT Position: Q4 2020 in Review

Roubaix Capital sold out of Health Catalyst (HCAT) in Q4 2020, closing a stake of 31,889 shares — an estimated $1.17M sold.

Roubaix Capital first reported a position in HCAT in Q1 2020 and held it in 2 quarters. The position peaked at $1.17M in Q3 2020. 168 funds tracked by Wall St. Rank hold HCAT as of Q4 2020.

Roubaix Capital reported no remaining Health Catalyst position as of Q4 2020 after selling out during the quarter.
Roubaix Capital sold 31,889 Health Catalyst shares in Q4 2020, an estimated $1.17M.
Roubaix Capital first reported a position in Health Catalyst in Q1 2020 and held it in 2 quarters.
Roubaix Capital's Health Catalyst position peaked at $1.17M in Q3 2020.
168 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2020.

Based on Roubaix Capital's 13F filing for Q4 2020, filed 11 Feb 2021.